Sajid Khan

10PUBLICATIONS
39CO-AUTHORS
Molecular targetsBiomolecular modelling and designCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 28, 2026
The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRASG12D Inhibitor Treatment.

Javed Miyan, Vignesh Vudatha, Lin Cao

|Jun 26, 2025
Targeting DDR2 for Treating Pancreatic Cancer.

Chris T P Do, Prabhakar Pitta Venkata, Jack Y Prochnau

|Mar 27, 2024
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.

Sajid Khan, Lin Cao, Janet Wiegand

|Jan 01, 2023
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.

Sajid Khan, Patrick Kellish, Nick Connis

|Mar 09, 2022
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.

Sajid Khan, Janet Wiegand, Peiyi Zhang

|Nov 26, 2021
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.

Dongwen Lv, Pratik Pal, Xingui Liu

Pageof 2

Frequent Collaborators

7 joint publications

Guangrong Zheng

6 joint publications

Daohong Zhou

4 joint publications

Xuan Zhang

3 joint publications

Weizhou Zhang